RESUMEN
Immunoglobulin M (IgM) is an evolutionary conserved key component of humoral immunity, and the first antibody isotype to emerge during an immune response. IgM is a large (1 MDa), multimeric protein, for which both hexameric and pentameric structures have been described, the latter additionally containing a joining (J) chain. Using a combination of single-particle mass spectrometry and mass photometry, proteomics, and immunochemical assays, we here demonstrate that circulatory (serum) IgM exclusively exists as a complex of J-chain-containing pentamers covalently bound to the small (36 kDa) protein CD5 antigen-like (CD5L, also called apoptosis inhibitor of macrophage). In sharp contrast, secretory IgM in saliva and milk is principally devoid of CD5L. Unlike IgM itself, CD5L is not produced by B cells, implying that it associates with IgM in the extracellular space. We demonstrate that CD5L integration has functional implications, i.e., it diminishes IgM binding to two of its receptors, the FcαµR and the polymeric Immunoglobulin receptor. On the other hand, binding to FcµR as well as complement activation via C1q seem unaffected by CD5L integration. Taken together, we redefine the composition of circulatory IgM as a J-chain containing pentamer, always in complex with CD5L.
Asunto(s)
Linfocitos B , Cadenas J de Inmunoglobulina , Inmunoglobulina M/metabolismo , Cadenas J de Inmunoglobulina/metabolismo , Linfocitos B/metabolismo , Antígenos , Macrófagos/metabolismoRESUMEN
BACKGROUND: Rheumatoid factors (RF) are one of the hallmark autoantibodies characteristic of rheumatoid arthritis (RA), and are frequently observed in other diseases and in healthy individuals. RFs comprise multiple subtypes with different specificities towards the constant region of human IgG. Studies indicate that these patterns differ between naturally occurring RFs and RFs associated with disease. However, individual specificities characteristic of either have not been clearly defined. METHODS: In this study, we developed an extended set of engineered IgG-fragment crystallisable (Fc) targets with preferential RF binding to specific (conformational) epitopes, which was subsequently used for profiling of RF binding patterns in a compiled exploration cohort, consisting of sera from healthy donors with measurable RF and patients with RA, primary Sjögren's syndrome (pSS) and seropositive arthralgia. RESULTS: We identified an epitope that is strongly associated with RA, which was targeted by both IgM-RF and IgA-RF. We also identified an epitope that is preferentially targeted by healthy donor (IgM) RFs. IgM-RFs derived from healthy donors and patients with RA and pSS all target distinct regions on the IgG-Fc, whereas overall, the IgA-RF repertoire is largely restricted to pathology-associated specificities. Using monoclonal RFs with different specificities, we furthermore demonstrate that the capacity to activate complement or even inhibit IgG-mediated complement activation varies according to the epitopes to which RFs bind. CONCLUSIONS: Our results demonstrate both the need and feasibility to redefine 'RF' into pathological and physiological autoantibody subtypes.
Asunto(s)
Artritis Reumatoide , Factor Reumatoide , Humanos , Autoanticuerpos , Epítopos , Autoinmunidad , Inmunoglobulina G , Inmunoglobulina M , Inmunoglobulina ARESUMEN
OBJECTIVES: Recently, we demonstrated that early low concentrations of circulating, adalimumab-bound TNF in RA patients treated with adalimumab was associated with future anti-drug antibody formation. Furthermore, low TNF was associated with less frequent baseline MTX use. This is remarkable, because of the anti-inflammatory effects of MTX and a potential inhibiting effect on cytokine production. We hypothesized an indirect effect of non-MTX use on low TNF concentrations via immunogenicity. To investigate the effect of MTX on TNF concentrations independent of anti-drug antibody formation, we measured TNF in RA patients treated with etanercept, a drug with low immunogenicity. METHODS: TNF was quantified in 186 consecutive etanercept-treated RA patients at baseline and at weeks 4, 16 and 28. The dynamics of TNF during etanercept treatment were compared with dynamics recently published for adalimumab. RESULTS: We demonstrated that TNF concentrations at week 4 did not associate with baseline MTX or remission after 28 weeks. Furthermore, median (interquartile range) TNF increased from <112 (<112-<112) pg/ml at baseline to 548 (344-688) pg/ml at week 4 and remained stable at week 16 and 28 [598 (442-756) and 568 (444-755) pg/ml, respectively]. CONCLUSION: Circulating TNF did not associate with MTX usage in etanercept-treated patients. This implies that MTX does not have a direct effect on TNF concentrations in circulation and that the association between early low TNF and non-use of MTX for adalimumab is thus most likely due to anti-drug antibody formation.
Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Etanercept/uso terapéutico , Metotrexato/uso terapéutico , Factor de Necrosis Tumoral alfa/sangre , Adulto , Artritis Reumatoide/sangre , Quimioterapia Combinada , Humanos , Resultado del TratamientoRESUMEN
Monitoring belimumab concentrations in patients can be a valuable tool for assessing treatment response and for personalizing drug doses. Various assay formats may be used to measure concentrations of therapeutic monoclonal antibodies. A particularly useful format involves the use of anti-idiotype monoclonal antibodies, selected to be highly specific to the antibody of interest. Here, we describe the development of a specific, high-affinity anti-idiotype antibody to belimumab, and the application of this antibody in a homologous sandwich ELISA to measure belimumab concentrations.
Asunto(s)
Anticuerpos Antiidiotipos , Anticuerpos Monoclonales Humanizados , Monitoreo de Drogas , Ensayo de Inmunoadsorción Enzimática , Anticuerpos Monoclonales Humanizados/uso terapéutico , Anticuerpos Monoclonales Humanizados/inmunología , Humanos , Ensayo de Inmunoadsorción Enzimática/métodos , Monitoreo de Drogas/métodos , Anticuerpos Antiidiotipos/inmunología , Animales , Inmunosupresores/sangreRESUMEN
Antibody formation to human(ized) therapeutic antibodies in humans is highly skewed toward anti-idiotype responses, probably because the idiotype is the only 'foreign' part of the antibody molecule. Here, we analyzed antibody responses to F(ab')2 fragments of a panel of 17 human(ized) therapeutic antibodies in rabbits. Homology between the rabbit germline and the human(ized) antibodies is moderate not only for the variable domains (both the complementarity-determining regions and the framework regions), but also for the constant domains (66% or less). Nevertheless, we observed a highly skewed anti-idiotype response in all cases, with up to >90% of the antibodies directed toward the idiotype. These results indicate that the idiotype may be inherently immunodominant. We used these biased responses to raise monoclonal rabbit anti-idiotype antibodies against secukinumab, ustekinumab, reslizumab, mepolizumab, palivizumab, and dupilumab and demonstrate the potential to develop sensitive pharmacokinetic assays with these antibodies.
Asunto(s)
Anticuerpos Antiidiotipos/inmunología , Anticuerpos Monoclonales Humanizados/inmunología , Anticuerpos Monoclonales/inmunología , Formación de Anticuerpos , Inmunización , Fragmentos Fab de Inmunoglobulinas/inmunología , Animales , Humanos , ConejosRESUMEN
PURPOSE: Training for improvement of oxidative capacity of muscle fibers may be attenuated when concurrently training for peak power. However, because of fiber type-specific recruitment, such attenuation may only account for high-oxidative muscle fibers. Here, we investigate the effects of concurrent training on oxidative capacity (as measured by succinate dehydrogenase (SDH) activity) by using task-specific recruitment of the high- and low-oxidative compartment of rat medial gastrocnemius muscle (GM). METHODS: Forty rats were subjected to 6 wk of peak power training (PT, n = 10), endurance training (ET, n = 10), concurrent peak power and endurance training (PET, n = 10), or no training (control, n = 10). SDH activity, mRNA expression of SDH, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), receptor-interacting protein 140, and BCL2/adenovirus E1B 19 kDa-interacting protein 3 as well as PGC-1α protein levels were analyzed in the low- and high-oxidative region of the GM. RESULTS: In the low-oxidative compartment, PT and PET induced a 30% decrease in SDH activity of Type IIB fibers compared with controls and ET (P < 0.001) without changes in mRNA or protein levels. In the high-oxidative compartment, after ET, SDH mRNA levels were 42% higher and RIP140 mRNA levels 33% lower compared with controls, which did not result in changes in SDH activity. CONCLUSION: These results indicate that in compartmentalized rat GM, peak power on top of endurance training attenuated transcription of mRNA for mitochondrial proteins in high-oxidative muscle fibers. In low-oxidative Type IIB fibers, peak power training substantially decreased SDH activity, which was not related to lower SDH mRNA levels. It is concluded that PT and PET enhanced mitochondrial degradation in the low-oxidative compartment of rat GM.